Frank Lupisella - C R Insider

BCR -- USA Stock  

null 331.24  0.00  0.00%

Mr. Frank Lupisella Jr., is Vice President, Controller of the Company. Mr. Lupisella joined Bard in 1987 and has served in various capacities in the finance organization of the company. Mr. Lupisella served as Vice President and Controller of the Davol division from 1999 until 2005 when he was promoted to Assistant Corporationrationrate Controller, Manufacturing Operations. In 2006, he was promoted to his present position of Vice President and Controller of the company.
Age: 55  VP Since 2006      
908 277-8000

Frank Lupisella Latest Insider Activity

Management Efficiency

The company has Return on Asset of 11.65 % which means that on every $100 spent on asset it made $11.65 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 30.56 % implying that it generated $30.56 on every 100 dollars invested.
The company has 1.64 B in debt with debt to equity (D/E) ratio of 81.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. C R Bard has Current Ratio of 1.69 which is typical for the industry and considered as normal.

Similar Executives

Found 5 records

VP Since

Rodney GonsalvesAgilent Technologies
Larry WoodEdwards Lifesciences Corporatio
Daniel MaloneWest Pharmaceutical Services
Patrick VerguetEdwards Lifesciences Corporatio
Donald BoboEdwards Lifesciences Corporatio

Entity Summary

C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. C R Bard (BCR) is traded on New York Stock Exchange in USA. It is located in 730 Central Avenue, Murray Hill, NJ 07974, United States and employs 14,900 people.

C R Bard Leadership Team

James Beasley, Group President
Patricia Christian, Vice President - Quality, Regulatory and Medical Affairs
Sharon Alterio, Group Vice President
Todd Garner, Vice President - Investor Relations
Marc Breslawsky, Independent Director
John Weiland, President, COO and Director
John DeFord, Senior Vice President - Science, Technology and Clinical Affairs
Frank Lupisella, Principal Accounting Officer, VP and Controller
Betty Larson, Vice President Human Resources.
John Groetelaars, Group Vice President
Tony White, Independent Director
Gerard Porreca, Vice President - Quality, Regulatory and Medical Affairs
Robert Davis, Director
Anthony Welters, Independent Director
Gail Naughton, Independent Director
John Kelly, Independent Director
Tommy Thompson, Independent Director
Samrat Khichi, Senior Vice President General Counsel, Secretary
Sharon Luboff, Group Vice President
Herbert Henkel, Lead Independent Director
Christopher Holland, CFO and Sr. VP
David Melcher, Director
Jim Beasley, Group Pres
Timothy Collins, Group Pres
Timothy Ring, Chairman, CEO and Chairman of Executive Committee
David Barrett, Independent Director

Stock Performance Indicators

Current Sentiment - BCR

C R Bard Investor Sentiment

Greater number of Macroaxis users are currently bullish on C R Bard. What is your opinion about investing in C R Bard? Are you bullish or bearish?
98% Bullish
2% Bearish

C R Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for C R and West Pharmaceutical. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try World Markets Correlation module to find global opportunities by holding instruments from different markets.